Tumor metastasis remains a major obstacle for improving overall cancer survival in cervical cancer (CC), which may be due to the existence of tumor microenvironment-related cancer stem cells (CSCs) and epithelialmesenchymal transition (EMT). The mechanism underlying these processes needs to be further elucidated. Here, we report that TGF-b1, one of the key microenvironmental stimuli, can enhance CSC characteristics, facilitate the EMT, and induce CK17. Silencing CK17 expression attenuated CSClike properties without affecting the EMT markers induced by TGF-b1, whereas forced overexpression of CK17 promoted lymphatic metastasis in vivo even without EMT inducement. Inhibitors of ERK1/2 signaling drastically decreased the induction of CK17 mediated by TGF-b1. By combined computational and experimental approaches, we identified and validated that MZF1 was a key transcription factor binding to the promoter of CK17. Taken together, these results demonstrate that CK17 induced by the TGF-b1-ERK1/2-MZF1 signaling pathway facilitates metastasis by promoting the acquisition of CSC properties rather than by inducing the EMT process in CC, suggesting that this CK17-related signaling pathway might be a suitable target for the development of therapy for CC metastasis.
Introduction
Despite advances in preventative and therapeutic strategies, including the increasing use of the human papillomavirus (HPV) vaccine, the wide application of cervical screening programs, and other comprehensive treatment regimens, cervical cancer (CC) remains the second leading cause of cancer-related deaths among women [1, 2] . Women with early stage CC or those with advanced but localized CC who undergo surgical resection or chemoradiotherapy, respectively, can often be cured. However, once patients suffer from a local invasion or the metastasis of CC (a large carcinoma extending beyond the cervix that involves vaginal and pelvic metastasis, usually classified as being between FIGO stages IB2 to IV) or from recurrent cervical cancer, the prognosis becomes poor, and more effective treatments are required. Tumor relapse and metastasis are the two primary causes of treatment failure and subsequent death in patients with cervical cancer.
Recently, cancer stem cells (CSCs), a small minority of stem-like cells within a tumor that are capable of self-renewal and tumor initiation and are multipotent and chemoradiotherapy resistant, have been implicated as the root cause of tumor recurrence and metastasis [3] [4] [5] [6] [7] . It is reported that CSCs not only can invade, disseminate through blood vessels or lymph vessels, seed distant sites, and colonize to macrometastases but also promote angiogenesis and lymphangiogenesis to promote metastasis. Due to the dreadful properties of CSCs, resurgence can occur after surgery, chemoradiotherapy, or even comprehensive treatment [8, 9] . Therapeutic approaches that specifically target the CSC population might substantially improve outcomes in patients with late-stage cancer [10] . Cervical cancer stem cells (CCSCs) have been identified, and a panel of cell antigens, including Nanog, Nestin, SOX2, OCT4, CK17, and ALDH1, have been shown to be promising markers of CCSCs [11] [12] [13] [14] [15] . Variations in these markers can affect the self-renewal, drug-resistance, antiradiotherapy, and oncogenic capacities of cervical cancer cells. However, some controversy exists concerning which antigens are unique and reliable markers of CCSCs. Signal transduction molecules and the cell's microenvironment, which play key roles in the activation of cell function, regulation of cell differentiation, and control of cell division, and which can disrupt the state of equilibrium and lead to uncontrolled cell growth and metastasis, determine the homeostatic niche that affects CSCs' stemness in vivo [16] [17] [18] [19] [20] [21] . Therefore, finding a reliable CCSC marker and conducting an intensive study of the complex network of signals that regulate the self-renewal and metastatic potential of CCSCs are essential for the development of a targeted therapy for CCSCs.
The microenvironment of CSCs (the CSC niche), which consists of cancer-associated fibroblasts, mesenchymal stem cells, and inflammatory cells and their secretory cytokines (e.g., TGF-b1, IL6, TNF-a), is responsible for maintaining the principle properties of CSCs, preserving their phenotypic plasticity, protecting them from the immune system, and facilitating their metastatic potential [22] . Transforming growth factor beta-1 (TGF-b1), an important factor in the CSC niche, is also one of the most important cytokines in the HPV-related cervical cancer microenvironment [23, 24] . It has been reported to induce the epithelialmesenchymal transition (EMT), a pivotal mechanism contributing to tumor invasion and metastasis. Recent studies have shown that inducing the EMT by forcing the expression of key transcription factors or by extrinsic stimulation of the microenvironment, such as the addition of TGF-b1, generates cells with the properties of stem cells. However, the relationship and regulatory mechanisms that exist among the tumor microenvironment, CSCs, and the EMT process in CC remain largely unknown.
In this study, we demonstrate that CK17 expression, induced by the TGF-b1-ERK1/2-MZF1 signaling pathway, facilitates lymphatic metastasis by inducing the acquisition of CCSC properties in cervical cancer in a manner separated from the EMT process.
Results

TGF-b1 promotes the acquisition of cancer stem cell properties and mesenchymal phenotypes in cervical cancer cells
Previous data have established the role of TGF-b1-induced EMT in multiple types of carcinomas, such as breast cancer, colorectal cancer, and bladder carcinoma [25] . In the present study, we examined whether TGF-b1 was also associated with the EMT in CC. We chose SiHa, an HPV-infected cell line, and C33a, an HPV-noninfected cell line, to conduct our research. After a 5-day exposure to TGF-b1 (10 ngÁmL À1 ), most CC cells acquired long spindles and bulky mesenchymal alterations (Fig. 1A) . We therefore analyzed a panel of epithelial and mesenchymal markers in control and TGF-b1-treated cells by western blot. A significant reduction in E-cadherin and an increase in vimentin and fibronectin were induced in TGF-b1-treated cells (Fig. 1B) . The result was also confirmed by immunofluorescence staining (Fig. 1C) .
The oncosphere formation assay and side population (SP) detection were performed to determine whether cervical cancer cells could also acquire CSC characteristics after exposure to TGF-b1. As shown in Fig. 1D , SiHa and C33a cells cultured in serum-free medium with TGF-b1 (10 ngÁmL
À1
) for 12-15 days formed obvious oncospheres, which showed the tumor-initiating capability. The quantity and volume of these oncospheres were significantly greater than those of the control cells cultured in serum-free medium without TGF-b1. SP cells are thought to be a subpopulation of CSCs [26] . After being incubated in TGF-b1, the proportion of SP cells was significantly increased (1.9% in SiHa cells and 1.5% in C33a cells, Fig. 1E ) relative to that in the control group (0.5% in SiHa cells and 0.4% in C33a cells; P < 0.05).
Based on the data above, we conclude that TGF-b1 can enhance the CSC characteristics and induce EMT in CC cells.
CK17 induced by TGF-b1 promotes lymphatic metastasis through the maintenance of stemness properties but not through EMT in CC Because CSCs have been referred as the root of tumor recurrence and metastasis, we aimed further to clarify the mechanism underlying TGF-b1-induced stemness. Several possible cervical CSC markers, including NANOG, NESTIN, SOX2, OCT4, CK17, and ALDH1 [11] [12] [13] [14] [15] 27] , were tested. First, we used a RNeasy Mini kit to purify total RNA from oncospheres treated with or without TGF-b1. Then, cDNA synthesis and qPCR were performed. Surprisingly, CK17 was expressed to a significantly greater degree than all other measured markers of CCSCs in both SiHa and C33a oncosphere cells treated with TGF-b1 ( Fig. 2A) , other stemness markers increased just a little or not.
To explore the role of CK17 in cervical cancer cells, we constructed CK17-depleting SiHa and C33a cell models using a CK17-specific shRNA and its relative negative control (Fig. 2B) , named as shCK17 and shctrl, respectively. The CK17-depleting SiHa, C33a cells and their control cells were used in oncosphere formation and SP detection assay with or without TGF-b1 treatment. Knockdown of CK17 impaired the ability to form colonies in SiHa and C33a cells to a much greater extent than that in control cells with TGF-b1-stimulation (P < 0.05; Fig. 2C,D) . It also resulted in a notably decreased proportion of SP cells in each cell line (P < 0.05; Fig. 2E ). TGF-b1 can trigger CSC phenotype through CK17 in CC cells.
To further determine the association between TGFb1 and CK17, we conducted in vivo experiments. Immunohistochemistry was applied to examine the expression of TGF-b1 and CK17 in successive human squamous cell carcinoma of cervix (SCC) tissue microarrays. A high expression of TGF-b1 was detected in 62.9% (44 of 70) of the samples, whereas a high expression of CK17 was detected in 65.7% (46 of 70) ( Table 1 ). As shown in Fig. 2F , there was also a strong correlation between CK17 and TGF-b1 overexpression (Table 1 , r = 0.441, P < 0.001). These data suggested that the activation of TGF-b1 signaling can induce CK17 expression in patients with SCC. With regard to clinical parameters, both TGF-b1 and CK17 were positively correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage of the SCC (P TGF-b1 < 0.001, P CK17 = 0.001) and with the occurrence of lymphatic metastasis (P TGFb1 = 0.002, P CK17 = 0.025) but not with other clinical parameters, such as age or pathology grade (Table 2) . Surprisingly, a logistic regression model indicated that the coexpression of TGF-b1 and CK17 was a significant high-risk factor correlating with the development of lymphatic metastasis in cervical cancer (Table 3 ,
Reports have indicated that the EMT generated cells with properties of stem cells, and the activation of the EMT is important for tumor metastasis [25] . Therefore, we questioned whether the CK17, which was shown closely correlated with CCSCs' properties in aforesaid results, would also be related to the EMT process induced by TGF-b1. We examined the expression levels of key EMT markers, such as Ecadherin, vimentin, and fibronectin by western blot analysis to evaluate the effect of TGF-b1-induced CK17 expression on the EMT process. As shown in Fig. 2G , the protein expression of key EMT markers was not apparently altered in the CK17-depleted cells. Therefore, we proposed that CK17 induced by TGFb1 might promote metastasis through the maintenance of stemness properties but not through the EMT in CC.
For further determination, we applied a popliteal lymph node metastasis model in vivo. First, we successfully established SiHa and C33a cells stably expressing CK17 cDNA. Because many stimuli can induce EMT in the tumor microenvironment, we used the vimentin RNAi lentiviral vector to inhibit the effect of EMT induced by the stimuli of the tumor microenvironment in vivo. Western blot showed that we successfully constructed the Vector-nc, Vector-siVimentin, CK17-nc, and CK17-siVimentin stable cell line in SiHa and C33a (Fig. 3A) . Stable expression of CK17 did not influence the expression of EMT-related markers, such as E-cadherin, vimentin, or fibronectin, whereas depletion of vimentin led to up-regulation of E-cadherin, but down-regulation of fibronectin. The eight stable cells were inoculated into the footpads of nude mice (n = 6/group, Fig. 3C ), respectively. The resulting footpad tumors and popliteal lymph nodes were enucleated and analyzed after 7 weeks. As shown in Fig. 3B , the expression of fibronectin or E-cadherin in the footpad tumors formed by the CK17-nc group or Vector-nc group cells of SiHa was similar (data of C33a cells are not shown). In addition, both of them displayed increased levels of fibronectin and decreased levels of E-cadherin compared with the CK17-siVim group tumors. Deletion of vimentin could disrupt the EMT in in situ tumors in vivo. Furthermore, we found that the lymph nodes formed from CK17-nc cells had larger volumes than those formed from Vector-nc cells (Fig. 3D) . However, the lymph node volumes formed from CK17-siVim cells similar to those formed from CK17-nc cells. Likewise, the ratios of metastatic to total dissected popliteal lymph nodes were markedly higher in the CK17-nc group (83.33% [5/6] (Fig. 3E,F) ; a similar number of metastatic lymph nodes was found in the CK17-siVim groups and CK17-nc groups. Taken together, these results indicate that silencing the expression of vimentin can block the occurrence of EMT in vitro and in vivo, whereas overexpression of CK17 can promote lymph node metastasis without EMT inducement in CC in vivo.
The results of the above experiments in vitro and in vivo showed that CK17 induced by TGF-b1
Variables n CK17 expression CK17 expression Low (n, %) High (n, %) P Sprearman correlation P promoted lymph node metastasis through the maintenance of stemness properties but not through EMT in cervical cancer.
ERK1/2 signaling pathway controls CK17 expression in CC cells
To understand the potential intracellular signal transduction mechanisms involved in the TGF-b1-induced upregulation of CK17, we examined several important TGF-b1-related signaling pathways by western blot analysis in SiHa and C33a cells (data of C33a cells are not shown), including the canonical Smad signaling pathway and noncanonical signaling pathways, such as the PI3K/ AKT and MAPK pathways [28] . Here, we observed activation of the Smad3, ERK1/2, and JNK pathways, as indicated by an increase in phosphorylated Smad3 and p42/p44 (p-ERK1/2) at 30 min-1 h after stimulation and of p-JNK at 15 min after stimulation, followed by a rapid decline to basal levels ( Fig. 4A ). Other signaling pathway indicators, including c-Jun NH 2 -terminal kinase (JNK), p38, MAPK, and Akt, were not activated at up to 4 h after TGF-b1 treatment and were excluded from further research in the present study. To test whether the three activated pathways were responsible for the regulation of CK17 by TGF-b1, cells were pretreated with a specific ERK1/2 inhibitor (U0126, 20 mM) for 2 h, a Smad3 inhibitor (SIS3, 5 mM) for 1 h, or a JNK inhibitor (SP600125, 10 mM) for 1 h, respectively. Furthermore, we collected cells at the time when the phosphorylated protein expression was most stimulated by TGF-b1. To detect the expression of p-ERK1/2, we collected cells after 30 min of treatment with TGF-b1, p-Smad3 after 1 h, and p-JNK after 15 min. Western blot analysis showed that the TGF-b1-induced expression of CK17 in SiHa cells was greatly reduced by U0126 but was not affected by SIS3 or SP600125 (Fig. 4B) . The dual-luciferase reporter assay showed the same results as the western blot analysis (Fig. 4C) . TGF-b1 could activate the activity of the CK17 promoter, whereas administration of U0126 but not SIS3 or SP600125 blocked this impact. qPCR were used and we got similar results (Fig. 4D) . Thus, we propose that TGF-b1 up- regulates the expression of CK17 via the activation of the ERK1/2 signaling pathway.
Candidate transcription factors of the CK17 promoter are identified
Once the ERK1/2 pathway is activated, phosphorylated ERK1/2 increases and translocates to the nucleus of the stimulated cells to enhance the downstream transcription factors, and thus influences the expression of the target genes [29] . Therefore, we explored the intermediate factors involved in the TGF-b1-ERK1/2-CK17 signaling pathway. Using successive 5 0 -truncations from position À1999 to +1 in the promoter region of CK17, we compared the luciferase activities of eight truncated CK17 promoters with or without TGF-b1 stimulation. Transient transfection by the À34/+1, and À183/+1 constructs only stimulated luciferase activity by 0.3-1.1-fold after TGF-b1 stimulation, whereas the À661/+1, À799/+1, À1013/+1, À1366/+1, and À1999/ +1 constructs significantly stimulated luciferase activity by 1.6-4.5-fold (Fig. 5A ). These data indicate that the 478-bp sequence between À183 and À661 plays an important role in TGF-b1-induced CK17 expression. To further clarify this regulation, we scanned the 478-bp sequence (À661 to À183) for transcription factor (TF) binding site motifs using the CONSITE database (http://consite.genereg.net/) and the TFSEARCH database (http://diyhpl.us/~bryan/irc/protocol-online/pro tocol-cache/TFSEARCH.html). Six TFs for putative binding sites were predicted (Fig. 5B) , including MZF1, CREB, E2F, SP1, Snail, and c-FOS. Because the E2F superfamily contains eight known E2F family members, we examined only two representative E2F members, E2F1 and E2F4.
MZF1 is the key transcriptional mediator of CK17
We performed dual-luciferase reporter assays to investigate further the identity of the TFs that activate CK17 expression. As shown in Fig. 6A , transient transfection of MZF1, c-FOS or E2F4, but not any other members, including CREB, E2F1, SP1, and Snail, resulted in a significant increase (P < 0.01) in the transactivation of the CK17 promoter (À661 to +1) in SiHa, C33a and 293T cells, whereas E2F1 attenuated the transactivation of the CK17 promoter. In addition, we found that MZF1 and E2F4 were up-regulated after TGF-b1 stimulation in SiHa cells (Fig. 6B) . The up-regulation of MZF1 or E2F4 decreased in cells pretreated with an ERK1/2 inhibitor (U0126). Although c-FOS decreased after exposure to TGF-b1 or U0126, it was significantly reduced by the costimulation of TGF-b1 plus U0126. E2F1 did not show any change during TGF-b1 stimulation. We obtained almost the same results in C33a cells (data of C33a were not shown).
To determine further whether the MZF1-, c-FOS-, and E2F4-binding sites were responsible for CK17 activation by TGF-b1 stimulation, we generated point mutations in the MZF1-, c-FOS-, or E2F4-binding sites of CK17 constructs. Point mutations in the c-FOS-and E2F4-binding sites were able to attenuate the basal CK17 promoter activity but not that stimulated by TGF-b1. In contrast, point mutations in the MZF1-binding site resulted in a substantial decrease in both TGF-b1-induced and basal CK17 promoter activity in SiHa and C33a cells (Fig. 6C , data of C33a cells are not shown), indicating a functional significance of Fig. 6 . MZF1 is an important transcription factor that induces CK17 transcription activated by TGF-b1. (A) Expression plasmids of predicted transcription factors were cotransfected with the CK17 promoter reporter plasmid in SiHa, C33a or 293T cells. Cell extracts were assayed for luciferase activity after 48 h. The luciferase activity was expressed as the magnitude of induced activity relative to the activity of the empty vector control. Data are shown as the mean AE SD from three independent experiments (*P < 0.05, one-way ANOVA). (B) Quantitative PCR results showed the mRNA expression of MZF1, E2F4, and E2F1 in TGF-b1-treated or untreated SiHa cells with or without pretreatment of U0126. Data are shown as the mean AE SD from three independent experiments (*P < 0.05, **P < 0.01,***P < 0.001, N/S: no significance, one-way ANOVA). (C) Site-directed mutagenesis was performed to disrupt the core sequences of MZF1, c-FOS, or E2F4 binding in the CK17-661 promoter. TGF-b1-induced promoter activity was blocked by MZF1-binding site mutations, but not c-Fos-or E2F4-binding site mutations, in the CK17-661 promoter region. (D) RT-PCR and western blot analysis showed that transient transfection of siRNA against MZF1, but not negative control siRNA (nc), effectively inhibited the TGF-b1-induced up-regulation of CK17 at 6 h after TGF-b1 treatment. Error bars, mean AE SD of three independent experiments. *P < 0.05, one-way ANOVA. (E) The expression of MZF1 and CK17 in CC tissue microarrays detected immunohistochemically. SCC tumors with remarkably positive expression of MZF1 had high CK17 expression of the tumor cells. Scale bar indicates 50um.
the proximal MZF1 site for the effects of TGF-b1 and for the basal CK17 promoter activity. Moreover, TGF-b1-induced up-regulation of CK17 mRNA or protein level at 6 h was also inhibited by transient transfection of small interfering RNA (siRNA) against MZF1 (Fig. 6D) . Furthermore, we examined the expression of MZF1 in the same human tissue microarray cohort to evaluate the relationship between MZF1 and CK17. As summarized in Table 4 , statistical analysis revealed no significant correlation between MZF1 expression and pathology grade (P = 0.755) or age (P = 0.130). In contrast, MZF1 correlated significantly with lymphatic metastasis (P < 0.001) and FIGO stage of SCC (P < 0.001). SCC tumors with remarkable nuclear staining of MZF1 had high CK17 expression of the tumor cells (Fig. 6E) . Spearman correlation analysis showed a positive correlation between MZF1 expression and CK17 expression ( Table 1 , r = 0.592, P < 0.001). Taken together, these results showed that although both MZF1 and E2F4 could activate the CK17 promoter, associated with the TGFb1-ERK1/2 signal pathway, only point mutations in the MZF1 binding sites of CK17 constructs were able to attenuate the TGF-b1-induced and basal CK17 promoter activity in SiHa and C33a cells. siRNA and immunohistochemistry also showed positive correlation between MZF1 and CK17. We concluded that MZF1 is a key transcriptional factor involved in TGFb1-ERK1/2-CK17 signal pathway.
Discussion
Metastasisis one of the most crucial processes in cancer progression and always portends a poor prognosis as metastatic foci germinate sporadically, making the patient resistant to therapies and, eventually, compromising the function of vital organs [16, 30] . More than 90% of cancer-associated mortality is due to metastasis [31] . Therefore, clinically preventing or targeting metastasis is urgently required. Increasing evidence suggests that the metastatic initiating cells are CSCs [4, 16] . In cervical cancer, as in other cancers, characterization of CSCs and their related signal pathways will allow for the development of new treatments that are specifically targeted against this critical population of CSCs, particularly their ability to metastasize. Recently the CSC niche, especially its secretory cytokines (TGF-b1, IL6, TNF-a, etc.), has been shown to be responsible for maintaining the tumor-initiating capacity of CSCs. In addition, the EMT process, a key developmental program that is often activated during cancer invasion and metastasis, has been reported to generate cells with stem cell-like properties also [23] . A better understanding of CSCs, the CSC niche factors and EMT, as well as the mechanism underlying these processes, is paramount for eliminating CSCs and metastasis, thereby eradicating tumors.
Transforming growth factor beta-1, a key cytokine in both the tumor microenvironment and the CSC niche, can be a suppressor of cell proliferation during the early stage of tumor growth but change to a promoter of tumor cell invasion and metastasis as the tumor develops [32] . Our preliminary experiments showed that TGF-b1 played an important role in tumor cell movement and lymphangiogenesis [33] . Recently, studies have indicated a role for TGF-b1 in driving EMT and promoting CSC maintenance [23] . In agreement with previous reports, we showed here that the cervical cancer cell lines treated with TGF-b1 underwent EMT, as did enriched cells with stemness, including mesenchymal morphology changes, downregulation of E-cadherin expression, up-regulation of fibronectin and vimentin expression, and increased oncospheres and SP population. However, whether TGF-b1 promotes EMT induction and stemness acquisition independently or concomitant, is still unclear.
Since Mani et al. [25] first reported the characteristic of stem cells that they could be induced simultaneously with the EMT induction. Accumulating evidence has shown the connection between the EMT and CSCs in human cancers [32] [33] [34] [35] [36] [37] [38] . Over the past decade, research has shown that factors inducing the EMT bestowed cells with stem-like characteristics, and certain CSCs also expressed EMT markers. It seems that the EMT and CSC are concomitant. However, the EMT was not always coupled with stemness [39] [40] [41] . Celia-Terrassa et al. demonstrated that EMT can suppress the self-renewal states of prostate and bladder cancer cells. Moreover, by knocked down Vimentin in the different cell lines to inhibit EMT, we found that overexpression of CK17 was more likely to produce tumors and lymph node metastasis, even without EMT inducement. This indicates that lack of EMT did not obstruct the CK17-promoted metastasis, EMT and CSCs might occur through different routes. Furthermore, the latter was suggested to be the primary reason of tumor recurrence and the transition of microscopic metastases into macroscopic metastases. An early study reported by Yang et al. [42] indicated that the high expression of stem cell marker OCT-4 was significantly correlated with lymph node metastasis. In addition, Brabletz et al. [43] reported that migrating cancer stem cells can disseminate and form metastatic colonies. Recently, CK17 was also shown to be a CSC marker, along with CD44, in cervical cancer [11] . CK17, a marker of cervical reserve cells [44] , was reported as an indicator of the risk for cervical cancer in patients, since positive expression of CK17 had been shown to be associated with the development of cervical lesions [44] [45] [46] [47] . The expression of CK17 was induced along with the progressive aggravation of lesions (from CIN to carcinoma). Indeed, our study also found that CK17 expression is critical for stem cell properties. Immunohistochemistry in human SCC tissue microarrays also showed that the high expression of CK17 correlated with the FIGO stage of the SCC and its lymphatic metastasis. Down-or upregulation of CK17 expression could affect the tumor initiation, tumor chemoresistance, and lymphangiogenesis. The results of our study clearly demonstrate that targeting CK17 and its associated pathways might provide an additional strategy for diminishing the CSC pool.
Transforming growth factor beta-1 triggers many intracellular signaling pathways, including Smad3, ERK1/2, JNK, PI3K, TGF-b-activated kinase 1 (TAK1), and others [48, 49] . Generally, Smad3 proteins are the key signaling inducers of the TGF-b pathway [48] . They are activated in all TGF-b-responsive cells and play central roles in the biological functions of the TGF-b family [49, 50] . Although accumulation of phosphorylated Smad3 was apparent in CC cells treated with TGF-b1, we found that the activation of ERK1/2 was more important in up-regulation of CK17. This was supported by the fact that U0126 pretreatment significantly abolished TGF-b1-induced CK17 promoter activity and CK17 expression. The ERK1/2 cascade regulates a variety of cellular processes, ranging from stimulation of cell survival and proliferation to triggering tumor suppressor responses such as cell differentiation, cell senescence, and apoptosis. We found that ERK1/2 stimulation was associated with CK17 expression, which promoted stemness acquisition. Comparable findings were reported by Zhang et al. [51] , who demonstrated that the CD44-p-ERK-OCT4-positive feedback maintained the properties of CSCs in gastric cancer.
In summary, our study demonstrates that CK17 isan important marker of CCSCs. TGF-b1-induced CK17 expression via the ERK1/2-MZF1 signaling pathway, promotes the stemness of cervical cancer cells without the influence of TGF-b1-induced EMT. The EMT and stemness in CC might occur through different routes, which is worthy of further exploration. Our finding uncovers and suggests that this CK17-related signaling pathway might be a suitable target for development of a therapy for cervical cancer relapse and metastasis.
Materials and methods
Cell culture and treatment
The cervical cancer cell lines SiHa and C33a were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Human embryonic kidney 293T cells were also obtained from the American Type Culture Collection. All cells were cultured in DMEM with 10% fetal calf serum at 37°C with 5% CO 2 . TGF-b1-stimulation experiments were performed with recombinant human TGF-b1 (Peprotech, Rocky Hill, NJ, USA).
Western blot
All cells were collected at their different, indicated time points. Cell lysates were prepared as described previously [52] . Forty micrograms of protein were fractionated by 10-12% SDS/PAGE and transferred onto 0.48-lm polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA, USA). The PVDF membranes were blocked with 5% BSA for 1 h before being incubated overnight at 4°C with primary antibodies, including anti-CK17 (1 : 1000), anti-Ecadherin (1 : 500), anti-vimentin (1 : 500), anti-p-Smad3 (1 : 1000), anti-Smad3 (1 : 1000) (Abcam, Cambridge, UK), anti-fibronectin (Santa Cruz Biotechnology, Dallas, TX, USA), anti-ERK1/2 (1 : 1000), anti-p-ERK1/2 (1 : 1000), anti-PI3K (1 : 1000), anti-p-PI3K (1 : 500), anti-p38 (1 : 1000), anti-p-p38 (1 : 500), anti-JNK (1 : 1000), anti-p-JNK (1 : 500), anti-GAPDH (1 : 1000) (Cell Signaling Technology, Beverly, MA, USA) and anti-MZF1 (OriGene Technologies, Inc., Rockville, MD, USA; 1 : 500). The membranes were washed three times with PBST (PBS buffer containing 0.1% Tween-20) and then incubated with HRPconjugated secondary antibodies (CST) for 1 h. After the final wash with PBST, the antibody staining intensities were detected using ECL chemiluminescence reagents (Pierce, Thermo Fisher Scientific Inc., Waltham, MA, USA).
Immunofluorescence
The cells were seeded and cultured on small confocal dishes. After 3 days of treatment with or without TGF-b1, the cells were fixed with 4% paraformaldehyde for 30 min, permeabilized with 0.1% Triton X-100 for 15 min (no shaking), and blocked with 5% BSA for 30 min. The cells were then incubated with anti-E-cadherin, anti-vimentin, and anti-fibronectin antibodies and mounted in VECTA-SHIELD mounting medium containing DAPI (Vector Labs, Youngstown, OH, USA). Images were obtained with an Olympus inverted fluorescence microscope (Olympus, Tokyo, Japan) and were outputted to FV10-ASW 1.7 Viewer software (Olympus) for analysis.
Oncosphere formation assay
The oncosphere formation assays were performed as described previously [25] . One thousand cells per well were placed in an ultra-low attachment 24-well flask (Corning, NY, USA) with or without TGF-b1. The cells were grown in serum-free DMEM-F12 (Hyclone, South Logan, UT, USA), supplemented with B27 (Invitrogen, Thermo Fisher Scientific Inc., Waltham, MA, USA), N2 (Invitrogen), 20 ngÁmL À1 EGF and 20 ngÁmL À1 bFGF (Peprotech).
Bovine pituitary extract was excluded. Appropriate culture medium was added every 2 days. After 12-15 days, the oncospheres were photographed and counted using an Olympus microscope, and the data were outputted to DP2-BSW software (Olympus, Center Valley, PA, USA) every 3 days for analysis. Inc., Palo Alto, CA, USA) was added to the cultures for selection. After 14 days, puromycin-resistant cell lines, Vector and CK17 were established. Then, we transfected the siVimentin and nc lentiviral particles into the two stable cell lines. The Vector-nc, Vector-Vim, CK17-nc, and CK17-siVim cell lines were constructed and referred to as Vectornc, Vector-Vim, CK17-nc and CK17-siVim. Cells were transfected with 10 nM MZF1 siRNA or a negative control siRNA (sense: GAGGCUGGCGAUUAC AUAATT, antisense: UUAUGUAAUCGCCAGCCUCTT; GenePharma, Suzhou, China) with Lipofectamine TM 2000 (Invitrogen) according to the manufacturer's instructions. The transfection efficiency was more than 90%, as confirmed by the detection of FITC-labeled siRNA (Invitrogen).
Side population detection
Immunohistochemistry staining and evaluation
Immunohistochemistry staining was performed on successive squamous carcinomas of the cervix (SCC) microarrays according to the manufacturer's instructions. Briefly, the tissue microarrays were deparaffinized and rehydrated. Endogenous peroxidase was inhibited with 0.3% H 2 O 2 . For antigen retrieval, the tissue microarrays were boiled in 0.01 M sodium citrate buffer (pH 6.0) for 5 min in an autoclave. After blocking with 5% normal goat serum, the primary anti-TGF-b1 polyclonal antibody (ZSJQ, 1 : 200), anti-CK17 monoclonal antibody (Abcam; 1 : 1000) and anti-MZF1 monoclonal antibody (OriGene Technologies; 1 : 200) were applied, as appropriate, and the microarrays were incubated at 4°C overnight. After incubation with a secondary antibody, the signal was visualized with diaminobenzidine.
The stained tissue microarrays were reviewed and independently scored by two pathologists blinded to the clinical parameters. TGF-b1 staining was observed primarily in the cytoplasm, CK17 staining was observed in the cytoplasm and membrane, and MZF1 staining was observed in the nucleus of cervical cells. The expression status of TGF-b1, CK17, and MZF1 of the entire area was determined as the product of the scores for the average extent and intensity of positively stained cells [53] . The scores for extent were defined as: 0, < 1%; 1, 1-30%; 2, 31-60%; and 3, > 60%. The scores for intensity were defined as: 0, none; 1, weak staining; 2, moderate staining; and 3, strong staining. The overall score combining the extent (E) and intensity (I) of staining was calculated as the product of E 9 I (expressed as EI). The mean EI score was calculated for each spot and varied from 0 to 9. EI scores of 0-3 were considered to represent low expression, and scores of 4-9 were considered to represent high expression. In 95% of the samples, the evaluations of the two observers were identical. The remaining slides were reevaluated, and consensus decisions were made.
Popliteal lymph node metastasis model
Animal experiments were conducted in accordance with standard procedures and approved by the institutional Use Committee for Animal Care. 4-to 6-week-old Balb/C athymic nude mice (nu/nu) were obtained from the Animal Center of Southern Medical University, Guangzhou, China. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Southern Medical University. The Balb/C nude mice were randomly divided into four groups (n = 6 per group). The Vector-nc, Vector-siVim, CK17-nc, or CK17-siVim cells (1 9 10 7 )
were inoculated into the footpads of the mice. Seven weeks later, the mice were sacrificed after anesthetized. The primary footpad tumors were removed using sterile ophthalmic scissors and then analyzed by qRT-PCR, and the popliteal lymph nodes were enucleated and measured with calipers. The popliteal lymph node volume was calculated as (length 9 width 2 )/2. Then the popliteal lymph nodes were paraffin embedded. Serial 4.0-mm sections were taken and detected by H & E staining and quantified by counting the metastatic lesions in each section.
Construction, deletion, and mutagenesis of the CK17 promoter
The human CK17 promoter region (À1999/+1) and its deletion variants (À1366/+1, À1013/+1, À797/+1, À661/+1, À183/+1, À34/+1) were obtained by PCR with different sense primers (show in Table 6 ) and the same antisense primer (5 0 -gatGCTAGCAGGCAGGCACACAGGAGAA G-3 0 ), using genomic DNA from PGL3-CK17 (which was purchased from FitGeneBioTechnology Co., Ltd, Guangzhou, China). The PCR products were digested with KpnI and NheI and then cloned into the luciferase reporter gene vector pGL3-basic (Promega, Madison, WI, USA) according to the manufacturer's protocol. The mutant CK17-661 promoter reporter construct was generated from the pGL3-CK17-661 construct using the KOD-Plus-Mutagenesis Kit (TOYOBO, Osaka, Japan). The mutagenesis primers are shown in Table 7 . To reduce the likelihood of PCR-generated mutations, all reactions were performed with Pfu DNA polymerase, and the amplified materials were verified by sequencing.
Dual-luciferase reporter assay
The expression plasmids of human Snail, E2F1, MZF1, SP1, E2F4, c-FOS, and CREB were purchased from FulenGen. All plasmids were sequenced to confirm their accuracy and lack of mutations. The luciferase assay was performed by transfecting human SiHa cells on day 1 with each of the above promoters or with the pGL3-basic vector, together with a trace amount (1/10 of the DNA amount for the test vector) of pRL-TK to express Renilla luciferase as an internal control. Lipofectamine 2000 was used for all transfections. The cells were treated with or without TGFb1 on day 2 and harvested on day 3 for the luciferase assay. Both the firefly and Renilla luciferase activities in the lysates were measured with the Dual-Luciferase Reporter Assay System (Promega) on an EnSpireTM 2300 Multilabel Reader (PerkinElmer, Waltham, MA, USA). The ratio of firefly luciferase activity to Renilla luciferase activity was obtained for each sample. Relative luciferase unit (RLU) values were calculated by normalizing each ratio for all groups to the average ratio for the control group. For the transactivation experiments on the seven potential transcriptional factors, 50 ng of each expression plasmid per well were cotransfected with the promoter vector and with pRL-TK. At 48 h after transfection, the relative luciferase activity was detected and analyzed as described above. Each assay was repeated in six independent replicates.
Statistical analysis
Statistical analyses were performed with SPSS 19.0 (IBM Corporation, Armonk, NY, USA). The differences between two or more groups were analyzed with unpaired Student's t-tests or one-way ANOVA. The v 2 test and Spearman correlation coefficient analysis were applied to evaluate the correlations between variables. Bivariate correlations were used to analyze the correlations between different datasets in relation to lymph node metastasis. Logistic regression models were fit to identify the factors that were significantly associated with CK17 expression levels and to the 
